The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 11, 2025

Filed:

Dec. 18, 2020
Applicant:

Oxford Drug Design Limited, London, GB;

Inventors:

Grace Edmund, London, GB;

Michael H. Charlton, Oxford, GB;

Paul William Finn, Faringdon, GB;

Aigars Jirgensons, Riga, LV;

Marija Skvorcova, Riga, LV;

Janis Veliks, Riga, LV;

Liene Grigorjeva, Riga, LV;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 381/10 (2006.01); C07C 313/06 (2006.01); C07D 213/71 (2006.01); C07D 215/36 (2006.01); C07D 231/18 (2006.01); C07D 277/16 (2006.01); C07D 307/79 (2006.01); C07D 317/50 (2006.01); C07D 333/34 (2006.01); C07D 333/52 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07C 381/10 (2013.01); C07C 313/06 (2013.01); C07D 213/71 (2013.01); C07D 215/36 (2013.01); C07D 231/18 (2013.01); C07D 277/16 (2013.01); C07D 307/79 (2013.01); C07D 317/50 (2013.01); C07D 333/34 (2013.01); C07D 333/52 (2013.01); C07D 495/04 (2013.01);
Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ-sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.


Find Patent Forward Citations

Loading…